Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ

Tapasi Rana¹, Anwesa Chakrabarti², Michael Freeman¹,², Swati Biswas¹,²*

¹ Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, ² Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, ³ College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Abstract
Breast cancer patients, who are already at increased risk of developing bone metastases and osteolytic bone damage, are often treated with doxorubicin. Unfortunately, doxorubicin has been reported to induce damage to bone. Moreover, we have previously reported that doxorubicin treatment increases circulating levels of TGFβ in murine pre-clinical models. TGFβ has been implicated in promoting osteolytic bone damage, a consequence of increased osteoclast-mediated resorption and suppression of osteoblast differentiation. Therefore, we hypothesized that in a preclinical breast cancer bone metastasis model, administration of doxorubicin would accelerate bone loss in a TGFβ-mediated manner. Administration of doxorubicin to 4T1 tumor-bearing mice produced an eightfold increase in osteolytic lesion areas compared untreated tumor-bearing mice ($P = 0.0002$) and an almost 50% decrease in trabecular bone volume expressed in BV/TV ($P = 0.0005$), both of which were rescued by anti-TGFβ antibody (1D11). Doxorubicin, which is a known inducer of oxidative stress, decreased osteoblast survival and differentiation, which was rescued by N-acetyl cysteine (NAC). Furthermore, doxorubicin treatment decreased Cu-ZnSOD (SOD1) expression and enzyme activity in vitro, and treatment with anti-TGFβ antibody was able to rescue both. In conclusion, a combination therapy using doxorubicin and anti-TGFβ antibody might be beneficial for preventing therapy-related bone loss in cancer patients.

Introduction
More than one million new cases of breast cancer are diagnosed worldwide annually. A major clinical complication of metastatic breast cancer is osteolytic bone destruction, and more than 75% of patients suffer from osteolysis, leading to increased fracture rate and poor quality of life. The overall life expectancy of breast cancer patients has improved in recent years, thereby increasing the patient population that suffers from cancer-induced bone loss, pathological fracture, spinal cord compression, bone pain and hypocalcaemia [1]. In addition, breast cancer patients often experience low bone mineral density and accelerated bone loss as an unavoidable side effect of cancer therapies [2]. While local bone resorption can be induced by the cancer cells at the metastatic site, commonly used cancer therapies often cause additional rapid and systemic bone loss, posing a major challenge in the long term management of patients with breast cancer.

Doxorubicin, an anthracycline agent, is widely used in chemotherapy regimens to treat both early stage and late stage metastatic breast cancer patients [3]. Multiple lines of evidence demonstrate several adverse effects of doxorubicin on bone. Childhood recipients of doxorubicin suffer long term bone damage in the form of reduced adult height and increased fracture risk [4]. A recent study indicated that premenopausal breast cancer patients treated with a doxorubicin/cyclophosphamide combination exhibited low bone mineral density and significant bone loss [5], suggesting a cause and effect relationship between doxorubicin treatment and systemic bone loss. Doxorubicin exposure caused a 60% reduction in bone formation in normal rats, suggesting a cause and effect relationship between doxorubicin treatment and systemic bone loss. Doxorubicin exposure caused a 60% reduction in bone formation in normal rats, suggesting a cause and effect relationship between doxorubicin treatment and systemic bone loss. Doxorubicin exposure caused a 60% reduction in bone formation in normal rats, suggesting a cause and effect relationship. Doxorubicin has also been shown to negatively regulate trabecular bone volume and cortical bone thickness in rabbits [8]. At a cellular level, doxorubicin has been reported to inhibit cell proliferation and parameters of cell differentiation in MC3T3 mouse osteoblasts [9]. Interestingly, Buttiglieri et al. have recently reported that doxorubicin treatment in cultured human mesenchymal stem cells reduced clonogenic ability and decreased osteoblast differentiation, accompanied by increased adipogenic potential [10]. These adverse effects heighten the concern for breast cancer patients who have received doxorubicin as a part of their treatment regimen, because these patients are already at high risk for bone loss and pathological fracture.

Thus far, the cellular and molecular mechanisms of doxorubicin-mediated bone loss are not known in the context of breast-to-bone metastases. In this regard, we have previously reported that doxorubicin exposure increases circulating levels of transforming growth factor-β (TGFβ) in normal and tumor-bearing mice [11].
In addition, Li et al. have reported that doxorubicin treatment can activate TGFβ/Smad signaling pathways [12]. TGFβ is sequestered throughout the skeletal system in its inactive form, making bone the largest source of TGFβ in the human body. TGFβ has been reported to increase osteoclast differentiation and suppress osteoblast differentiation [13], both of which may contribute to pathologic bone loss. TGFβ may also regulate the biochemical properties of bone by controlling bone mass and bone matrix properties [14], and genetic manipulation of this pathway affects bone mass in murine models [15], [16], [17], [18]. Increased TGFβ has been implicated in bone fragility and osteoporosis [16]. We and others have reported that blocking excess TGFβ in the bone, either by antibodies [19,20] or by small molecule inhibitors [21], is favorable for bone formation. Increased TGFβ has been implicated in induction of reactive oxygen species (ROS) [22], which also agrees with the fact that doxorubicin increases oxidative stress. Several reports have indicated that increased oxidative stress negatively impacts bone formation by modulating the differentiation and survival of osteoblasts [23], [24] and by increasing bone resorption [25], [26]. In addition, ROS accumulation and dysregulation of the antioxidant system are shown to be important mediators of bone loss [27], [28], [29], [30]. Based on these, we hypothesized administration of doxorubicin would accelerate bone loss in a TGFβ-mediated manner.

In this study, we aim to determine the cellular and molecular mechanism of doxorubicin-mediated bone injury in preclinical models of breast cancer to bone metastases. Our data demonstrate, co-administration of doxorubicin with 1D11, a pan-TGFβ antibody that blocks all three isoforms of TGFβ, significantly increased bone volume and decreased osteolytic bone damage. Interestingly, in MC3T3 osteoblast cells, treatment with doxorubicin was able to decrease the level of SOD1, a cytosolic antioxidant enzyme which plays an active role in protecting against oxidative stress by conversion of superoxide radical to hydrogen peroxide [31,32]. Overproduction of ROS has been implicated in bone resorption [26,33], osteoporosis and bone fragility [24,34,35]. Furthermore, treatment with doxorubicin also inhibited SOD1 enzyme activity in MC3T3 cells. Data presented here indicate treatment with anti-TGFβ antibody was able to restore both SOD1 expression and enzyme activity. Taken together our finding suggests that doxorubicin treatment directly contributes to bone damage by increasing oxidative stress and decreasing SOD1 expression and activity, likely via a TGFβ-mediated process. To our knowledge, it is the first report of doxorubicin mediated bone damage in preclinical breast cancer models.

Results

Doxorubicin Treatment Increases Bone Loss in Non-tumor and Tumor Bearing Mice

An orthotopic model of 4T1-592 breast cancer bone metastasis was used to investigate doxorubicin bone loss (Figure 1A and 1B). Both tumor-bearing and non-tumor bearing mice have shown doxorubicin-mediated bone loss. To test whether treatment with doxorubicin may provoke additional bone loss in breast cancer bone metastases models, we have compared trabecular bone volume in age-matched non-tumor bearing and tumor-bearing animals, treated once a week either with PBS or doxorubicin (5 mg/kg body weight) for 4 weeks. MicroCT analyses of mouse tibiae were performed to assess bone loss in both non-tumor bearing and tumor bearing mice, following doxorubicin treatment (Figure 1C). A significant amount of bone loss was observed in non-tumor bearing animals (Figure 1D) upon doxorubicin treatment (P = 0.001). Bone loss was significantly amplified when the mice were injected with 4T1-592 tumor cells in the #4 mammary fat pad of 4 week old female Balb/C mice (P = 0.0005). Both the non-tumor and tumor-bearing animals used in these experiments were of a congenic Balb/C background. Athymic nu/nu mice yielded a similar trend of bone loss following doxorubicin treatment (Figure 1E). When we used an intra-cardiac injection model using 4T1 cells, osteolytic lesions were detected at 4 weeks post-injection using radiographic images (Figure 1F). Our data indicate that doxorubicin treatment significantly (P < 0.001) increased osteolytic lesion area and lesion numbers compared to the control group (Figure 1G, H), suggesting that treatment with doxorubicin further increases bone destruction in tumor-bearing mice.

To assess the direct effect of doxorubicin on bone resorption, we used RatLaps ELISA to measure bone-related degradation products from C-terminal telopeptides of type I collagen from the serum samples of the non-tumor bearing nu/nu mice treated with either PBS or doxorubicin (5 mg/kg) for 4 weeks. The average amount of RatLaps (ng/ml) in the doxorubicin treatment group was significantly higher (P = 0.05) than in the control group (Figure 1I), suggesting that doxorubicin promoted bone resorption, even in the absence of a tumor in the bone microenvironment.

Anti-TGFβ Antibody Treatment Improves Doxorubicin-mediated Inhibition of Osteoblast Differentiation and Increases the Frequency of Osteoblast Colony Forming Units

Previous reports have indicated that doxorubicin treatment inhibits cell proliferation and parameters of cell differentiation in MC3T3 mouse osteoblasts [9] as well as reduced clonogenic ability and decreased osteoblast differentiation in cultured human mesenchymal stem cells [10], however the mechanism is not well understood. We have previously reported that doxorubicin treatment results in a systemic increase in the levels of TGFβ [11] and that blocking TGFβ may reverse pathological bone loss [19]. Here we tested whether treatment with the anti-TGFβ antibody 1D11 may protect bone marrow stromal cells and osteoblasts against doxorubicin-mediated damage. To determine this, bone marrow stromal cells were flushed from the long bones of non-tumor bearing C57BL/6j mice, plated at clonogenic density, and cultured for 15 days either in medium only, doxorubicin (0.01 μg/ml), 1D11 (25 μg/ml), or a combination of doxorubicin and 1D11. The medium used was appropriate to respectively support the growth of either fibroblast colony forming units (CFU-F) or osteoblast colony forming units (CFU-OB) culture as described under Materials and Methods. Our results indicate that treatment with doxorubicin causes a highly significant decrease in both fibroblast (P = 0.003) and osteoblast (P = 0.013) colony forming units and concurrent treatment with 1D11 was able to significantly improved numbers of both CFU-Fs (P = 0.013) and CFU-OBs (P = 0.013) (Figure 2A, B). Doxorubicin treatment affected the fibroblast population drastically by reducing the number of CFU-Fs by almost 90%, whereas number of CFU-OBs was reduced nearly 50%. Interestingly, treatment with 1D11 increased the number of CFU-OBs even higher than untreated control, suggesting a direct positive effect of anti-TGFβ antibody treatment on osteoblast colony forming units.

To investigate whether doxorubicin-mediated bone loss in non-tumor bearing mice is due to a detrimental effect of this chemotherapeutic agent on osteoblast mineralization, a crucial step for new bone formation, we used an ex vivo osteoblast mineralization assay. Osteoblast differentiation assay was per-
formed using bone marrow stromal cells in presence doxorubicin (0.01 μg/ml), 1D11 (25 μg/ml) or a combination of both as described in the Materials and Methods section. Doxorubicin treatment significantly ($P = 0.03$) decreased the osteoblast mineralization compared to control (Figure 2C). Treatment with 1D11 increased osteoblast mineralization compared to untreated controls, which was consistent with our earlier report [19]. Taken together, our data indicate that treatment with the anti-TGFβ antibody 1D11 may protect against doxorubicin-mediated damage by promoting osteoblast survival and differentiation.

Consistent with decreased osteoblast differentiation, an increase in RANKL expression was noted in MC3T3 cells upon treatment with doxorubicin which was restored to normal level following 1D11 treatment (Figure 2D), while, the level of OPG remained unaltered. In addition, treatment with doxorubicin has decreased the expression of both OPN and OCN in MC3T3 cells (Figure 2D).

Doxorubicin Increases Osteoclast Formation

Ex vivo osteoclast formation was performed as described under Materials and Methods. In brief, bone marrow mononuclear cells were isolated from either spleen or bone marrow of adult mice and cultured using osteoclast differentiation media alone or containing (0.01 μg/ml) doxorubicin, (25 μg/ml) 1D11, or a combination of both. Upon doxorubicin treatment, a significant increase in average osteoclast numbers was noted in cultures from both spleen ($P = 0.02$) and bone marrow mononuclear cells (Figure 2B, $P < 0.0001$). Interestingly, 1D11 was able to decrease osteoclast numbers to the basal level. Moreover, 1D11 treatment alone did not show any change in the osteoclast numbers.

Osteoblasts and preosteoblasts maintain the homeostasis of osteoclasts in bone microenvironment by secreting both OPG and RANKL [36], [37], [38], [39], [40]. To test whether treatment with doxorubicin may affect osteoblast-mediated osteoclast formation, we exploited a co-culture assay system. Bone marrow mononuclear cells and calvarial osteoblasts from adult non-tumor bearing C57BL/6J mice were used in this experiment, as described in the Materials and Methods section. Our result...
showed a statistically significant increase in osteoblast-mediated osteoclast numbers after treatment with doxorubicin treatment ($P = 0.005$), and 1D11 treatment restored the osteoclast numbers to a normal level (Figure 3C). This supports our previous finding that treatment with doxorubicin probably induces TGFβ, which in turn modulates the RANKL/OPG ratio and favors osteoclast formation, both directly and indirectly.

**Anti-TGFβ Antibody Treatment Rescues Doxorubicin-mediated Bone Loss in Preclinical Breast Cancer Bone Metastasis Models**

We have previously reported that doxorubicin increases circulating levels of TGFβ, a prometastatic cytokine implicated as a major driver of the vicious cycle of bone metastases. We hypothesized that, treatment with doxorubicin will increase bone loss in our preclinical models in a TGFβ dependent manner. MicroCT analyses of mouse long bones revealed that doxorubicin treatment resulted in significant decrease in trabecular bone volume (measured as BV/TV) in all tumor-bearing mice compared to untreated control. Bone loss in these mice was rescued by the anti-TGFβ antibody treatment (Figure 4B, G, I). Histological analysis also indicated that, in mice injected with MDA-MB-231 cells, trabecular bone area was significantly decreased (Figure 4C, $P = 0.003$) following treatment with doxorubicin and 1D11 was able to rescue bone area. In the MDA-MB-231 cardiac injection model, further analysis using quantitative microCT showed a statistically significant decrease in number of trabeculae upon doxorubicin treatment compared to the control group, which was restored to the normal level upon treatment with 1D11 (Figure 4D). Our treatment with doxorubicin did not affect the trabecular thickness as such, however, 1D11 treatment has generally improved trabecular thickness, underscoring its potential as a bone anabolic agent (Figure 4E).

**Doxorubicin Mediates Bone Damage via Increased Oxidative Stress**

Increased and persistent oxidative stress has been associated with doxorubicin-mediated cardiotoxicity [41]. To determine whether treatment with doxorubicin also increases oxidative stress in the bone marrow stromal cells, uptake of C400 measured as described in the Materials and Methods section. Treatment with doxorubicin significantly ($P<0.0005$) increased the number of C400 positive cells suggesting an increase in oxidative stress upon doxorubicin treatment (Figure 5A, and histogram presented in...
Discussion

Doxorubicin is a widely used anthracycline drug for patients suffering from primary as well as metastatic breast cancer [3] and has an overall response rate of up to 50%. With current therapeutic options, patients with metastatic disease show a median survival of about 2 years. However, the enthusiasm over usage of doxorubicin has dampened due to a number of side effects such as myelosuppression, immunosuppression and cardiotoxicity [43]. In addition, preclinical and clinical reports from patients with childhood cancers have indicated significantly disruptive side effects on the skeletal system including increases in pathologic fracture [44,45], reduced bone mineral density, diminished bone formation [7], and compromised adult height. Despite several reports of the damaging effect of doxorubicin on bone cells, not much was known about whether treatment with this agent may accelerate bone loss in breast cancer patients, who are already suffering from osteolytic disease.

In the context of metastatic breast cancer, when the cancer cell reaches the bone microenvironment, an increase in osteoclastic bone resorption takes place. As a result, an excess of active TGFβ is secreted in the bone microenvironment, which in turn mediates a cascade of events that favor the vicious cycle of bone metastasis [46]. In addition, TGFβ increases osteoclast differentiation [47], [48], and suppresses osteoblast differentiation [49], all of which may contribute to the accelerated bone destruction. We have previously reported that treatment with doxorubicin can increase circulating levels of TGFβ in both normal and tumor-bearing mice [11]. In addition, we and others have shown that blocking TGFβ either by antibodies or small molecules can prevent metastatic progression in the bone [19,50] and that suppression of TGFβ improves the overall bone volume in normal and tumor-bearing animals [20,51]. Interestingly, Bandyopadhyay et al. [52] have recently reported that combined treatment doxorubicin and a small molecule inhibitor of TGFβ receptor kinase [53,54] improved doxorubicin’s efficacy in the inhibition of breast cancer growth and metastasis. Previously, Bandyopadhyay et al have also reported an increase in metastatic incidence and tumor load in the bone using the 4T1 model [52]. We also observe a similar trend in our study (Figure S1). We anticipate that the increase in tumor incidence following doxorubicin treatment may have been an understudied area. However, as doxorubicin increases TGFβ in the circulation, it is not unlikely that doxorubicin regimen may negatively affect tumor load when it has spread to the bone. Further clinical studies are needed to assess the bone metastases in the patient population receiving doxorubicin.

Chemotherapy can induce bone loss both directly [55] and indirectly due to ovary failure. Apart from its indirect effects on bone, several studies have indicated that doxorubicin exposure directly affects matrix production by osteoblasts and decreases osteoid volume [56]. Trabecular bone volume was also reduced in doxorubicin-treated normal rat [7]. In agreement with these previous findings, we found that doxorubicin treatment can significantly increase bone loss in preclinical models of breast-to-bone metastasis. In addition, loss of trabecular bone volume and an increase in bone resorption markers was also noted in non-tumor bearing mice, suggesting a tumor-independent effect of doxorubicin on the bone microenvironment. At the cellular level, doxorubicin treatment decreased osteoblast differentiation when used in vitro. We anticipate that in vivo treatment with doxorubicin may also decrease stromal and osteoblast cell survival and disrupt bone homeostasis. This is in agreement with the previous report by Guest et al. [57] showing that, a single dose of doxorubicin (10 mg/kg) has completely inhibited the stromal cell population in bone metastases.
Figure 4. Anti-TGFβ antibody rescues doxorubicin mediated bone loss in breast cancer bone metastasis. MDA-MB-231 cells (1×10^6) were inoculated via left cardiac ventricle of four-week old female athymic nude mice and treated with PBS, doxorubicin (5 mg/Kg, once weekly for 4 weeks, i.p.), 1D11 (10 mg/Kg, three times per weekly for 4 weeks) and a combination of doxorubicin and 1D11 for three weeks. (A) Representative microCT images of mice tibiae from each treatment group (B) Quantification of trabecular bone volume (BV/TV), (C) Histology of mice tibia from each group revealed trabecular bone loss upon doxorubicin treatment, both of which were rescued upon anti-TGFβ antibody treatment. Quantification of (D) average trabecular numbers and (E) average trabecular thickness. Representative microCT images from tumor-bearing mice in which (F) 4T1 cells (10^5) were inoculated either via intracardiac route or (H) in the mammary fat pad of four-week old female Balb/c mice which received either PBS, doxorubicin (5 mg/Kg, once weekly for 4 weeks, i.p.), 1D11 (10 mg/Kg, three times per weekly for 4 weeks) or a combination of doxorubicin and 1D11 for three weeks. Quantification of microCT images show significant loss of trabecular bone volume (BV/TV) in both intracardiac (G) and orthotopic (I) models. At least 5 mice were assessed in each group and P<0.05 was considered significant.

In addition, ex vivo culture of bone marrow mononuclear cells have revealed that doxorubicin treatment increases osteoclast differentiation. However, when histological analysis was performed, the number of osteoclasts also decreased in the doxorubicin treated tumor-bearing mice, when compared with untreated tumor-bearing mice. We attribute the latter finding to severe damage of the bone marrow progenitor population, as previous reports have speculated that long term doxorubicin treatment results in a cytotoxic action on both osteoblasts and osteoclasts [8]. Using a co-culture assay system, we have also shown that doxorubicin treatment increased osteoblast-mediated osteoclastogenesis. This emphasizes an indirect yet very important role for osteoblasts in affecting doxorubicin-induced osteolytic bone damage.

We have demonstrated that treatment with doxorubicin can severely suppress osteoblast differentiation, and anti-TGFβ antibody treatment can restore this to normal level. Of note, doxorubicin administration was shown to decreased bone formation in young rat [7]. In addition, both the stromal and osteoblast progenitor survival were also disrupted upon doxorubicin treatment, suggesting long-term damage in the bone marrow microenvironment.

One of the objectives of this study was to identify a molecular mechanism by which doxorubicin accelerates bone loss. Increased TGFβ has been implicated in increased production of ROS. Our data indicate that, treatment with doxorubicin increases reactive oxygen species in MC3T3 osteoblast cells, which was accompanied by a decrease in SOD1 expression. In addition, following doxorubicin treatment, an inhibition of SOD1 enzyme activity was also noted which was rescued by anti-TGFβ antibody treatment.
Interestingly, it has been recently reported that loss of SOD1 decreases osteoblast viability and induces bone loss in mice [63]. Smietana et al have reported that loss of SOD1 resulted in weaker bone and lower bone mineral density in mice [64]. SOD1 has been reported to restore osteoblast differentiation by attenuating oxidative stress in human dental pulp cells [65], which is in agreement with our result that treatment with antioxidant agent NAC was able to rescue doxorubicin-mediated decrease in osteoblast differentiation. An inverse relationship was noted between TGFβ1 and SOD1 activity in radiation-mediated fibrosis models [66,67].

Since doxorubicin is known to significantly increase oxidative stress, we suspect other antioxidant enzyme may also play a role in the tissue injury mediated by this agent. In agreement with this, an increase in the GPx level was noted in MC3T3 cells upon doxorubicin treatment, with no change in catalase and HO1 levels. Earlier studies have indicated an increase in GPx activity in elderly people who exhibit higher oxidative stress due to natural aging [68] and GPx level was increased following doxorubicin treatment in human lymphoblastoma cell line (with functional p53) [69], whereas catalase level was not increased.

In conclusion, our data indicate, treatment with doxorubicin deregulates multiple pathways in bone marrow stromal cells and blocking TGFβ may rescue those events and prevent doxorubicin mediated bone loss. While doxorubicin-mediated oxidative stress have been implicated in cardiotoxicity, to our knowledge, this is...
the first report of SOD1 being the molecular target of doxorubicin-mediated bone damage. Based on this finding and those that indicate that TGFβ blockade can prevent metastatic progression to bone, we conclude that treatment with anti-TGFβ antibody 1D11 may have a two-fold benefit for the breast cancer patients by both inhibiting cancer progression and preventing bone loss. We anticipate this finding will lead to improved management and patient care for breast cancer survivors who have received doxorubicin as a part of their treatment regimen.

**Materials and Methods**

**Study Design**

Tumor bearing and non-tumor bearing mice were treated using 5 mg/kg doxorubicin (Sigma: Doxorubicin hydrochloride, D1515), once weekly for three weeks. For in vivo rescue experiments related to anti-TGFβ treatment, both the control antibody and the anti-TGFβ antibody (1D11) were obtained from Genzyme Corporation. 1D11 blocks all three isoforms of TGFβ [19]. To test the efficacy of anti-TGFβ antibody in preventing doxorubicin-mediated bone loss in both intracardiac and orthotopic model of breast cancer metastasis to bone. Mice were treated with anti-TGFβ antibody (1D11, 10 mg/kg), starting either 1 day (intracardiac) or 1 week (orthotopic) after tumor cell inoculation; treatment frequency was 3 days per week. The vehicle used for preparing the antibodies showed no significant difference compared to the control-antibody-treated group during initial experiments and was therefore excluded from these studies (communication with Genzyme Corporation). The outcome measures included quantification of trabecular bone volume (BV/TV), trabecular numbers and trabecular thickness from microCT of tibiae and histological analyses. Animals were sacrificed after three weeks and within this period we have not seen any drastic issue with survival. However, a expected, mice treated with doxorubicin had a rapid weight loss compared to other groups. We have measured body weight of the animals every other day throughout the study. Our animal care regulation dictates that we sacrifice the mice if any treatment lead to more than 10% weight loss. All mice which were alive after three weeks were used for the analysis. We have seen occasional death of mice before three weeks and those mice were excluded from the analysis.

**Cell Culture**

Bone metastatic variant of MDA-MB-231 was generated as described earlier [19]. In brief, MDA-MB-231 human breast cancer cell line was obtained from ATCC (American Type Culture Collection) and a bone metastatic variant generated previously in the group was used for all in vitro studies [70]. The murine mammary cell line 4T1 had previously been obtained from another investigator [71] and used in a cardiac injection model within our group. Both cell lines were maintained in DMEM (Invitrogen, Carlsbad, CA) containing 10% Fetal Bovine Serum (FBS; HyClone Laboratories, Logan, UT) and 1% penicillin/streptomycin (Mediatech). Cells were cultured in a 37°C atmosphere of 5% CO₂ and 95% O₂ using standard tissue culture techniques. 4T1-592 cells were generated as described earlier and we have received it from a collaborator Dr. F Elefteriou, Director, Center for Bone Biology, Vanderbilt University [72,73].

**Animals**

All procedures were performed with the approval of the Vanderbilt University Institutional Animal Care and Use Committee and in accordance with Federal guidelines. For all in vivo experiments, 4- to 5-week-old female athymic nu/nu mice (for MDA-MB-231 human breast cancer cells) or Balb/C mice (for 4T1 mouse mammary tumor cells) were used. Both athymic nu/nu mice and Balb/C mice were purchased from Harlan Laboratories.

**Intra-cardiac Bone Metastasis Model**

Intra-cardiac injection was performed as described earlier [19]. MDA-MB-231 or 4T1 cells were trypsinized, washed and then resuspended in ice-cold sterile PBS at a final concentration of 1×10⁶/mL. Four- to five-week-old female nude or Balb/C mice were anesthetized using a ketamine/xylazine mixture. Mice were positioned ventral side up, and tumor cells were injected into the left cardiac ventricle using a percutaneous approach with a 27-gauge needle, as described previously [74], [75]. Each mouse received 1×10⁵ cells in a 100-μl volume (resuspended in PBS). Treatment was started either from the next day (intra-cardiac) or 1 week (mammary fat pad injection) following tumor cell injection. Mice were imaged weekly and sacrificed as described under each experiments. Any mice showing signs of distress were sacrificed immediately.

**Orthotopic Bone Metastases Model**

For orthotopic breast cancer to bone metastases model, 4T1-592, 50 μL of a PBS solution containing 5×10⁵ cells were injected into the 4th mammary fat pad of 4 week old female Balb/C mice. After 1 week, palpable tumor was noticed and treatment with doxorubicin and/or antibodies were started.

** Colony Formation Assays**

Bone marrow cells were collected from the tibiae and femora of adult C57BL/6 mice using a PBS and antibiotic mixture (2000 U/ml penicillin and 2000 U/ml streptomycin). Cells were washed in 250 g for 5 minutes and supernatant was aspirated. Cells were resuspended in medium (α-MEM, 10% FBS, 2000 U/ml penicillin, 2000 U/ml streptomycin, and 250 μg/ml fungizone) and plated for at least 48 hours. After 48 hours, unattached cells were aspirated and attached cells were trypsinized, resuspended in single cell suspensions, counted and plated in appropriate cell density for colony formation assays. The fibroblast colony forming unit (CFU-F) assay was done using 10² cells per well and the osteoblast colony forming unit (CFU-OB) assay with 2×10² cells per well in a 6-well plate as previously described [76]. Cells were allowed to attach overnight and treatment with doxorubicin and/or 1D11 were started from one day after the cells were plated. Cells were treated with media supplemented with doxorubicin (0.01 μg/ml), 1D11 (25 μg/ml), or a combination of both. A control set was cultured using media alone. After visible colonies were noted, cells were fixed by 10% formalin and stained with 0.5% crystal violet for CFU-F and with Von Kossa for CFU-OB assays. Numbers of colonies were counted under a microscope.

**Osteoblast Mineralized Matrix Formation Assay**

Calvarial osteoblasts were isolated from 3- to 4-day-old mice pups, using a modification of a sequential collagenase/trypsin digestion method [77]. In brief, calvaria were removed from 3- to 4-day-old C57BL/6j mice. Soft tissues were cleaned, washed for 10 minutes with PBS containing 0.025% trypsin, digested with 10 mg/ml type-IV collagenase p (Clastrium histolyticum, Roche) in α-MEM, and incubated for 30 min at 37°C with gentle shaking. The procedure was repeated twice, with a 1-hour digestion followed by a 30-minute digestion. The cells from the second and third digestions were collected and centrifuged at 2500×g for
Osteoclast formation using a Leucocyte Acid Phosphatase kit (Sigma) following the manufacturer's instructions and cultured for 7–10 days. Bone marrow mononuclear cells were isolated using Histopaque 1077 (Sigma) and plated on top of the osteoblast layer. The co-culture system was treated with doxorubicin (0.01 μg/ml) and 1D11 (25 μg/ml) every other day for 7–10 days. Cells were fixed and stained for assessment of mature osteoclast formation using a Leucocyte Acid Phosphatase kit (Sigma) according to the manufacturer’s instructions, and mature osteoclasts (red) were counted using a microscope.

Osteoclastogenesis Assays

Osteoclast differentiation assays were performed as reported previously [19]. Briefly, mouse long bones were flushed with PBS, resuspended by pipetting, and strained through a 40 μM cell strainer (BD Biosciences, San Jose, California). Bone marrow mononuclear cells were isolated using Histopaque 1077 (Sigma) following the manufacturer’s instructions and cultured for 7–10 days in α-MEM supplemented with 10% FBS, 100 ng/ml RANKL (R&D systems) and 30 ng/ml macrophage colony stimulating factor (MCSF; R&D systems) to support osteoclast differentiation. TRAP staining was performed using a Leukocyte Acid Phosphatase kit (Sigma) with changes every 2 days until mineralized nodules are formed (approx. 15–21 days). Mineralized matrix formation was detected by Von Kossa staining, and photomicrographs were taken.

Measurement of Cellular ROS by Flow Cytometry

Femora and tibiae were collected from adult C57BL/6j mice and bone marrow cells were washed using sterile PBS and antibiotic (2000 U/ml penicillin and 2000 U/ml streptomycin), resuspended (α-MEM, 10% fetal bovine serum (FBS), 2000 U/ml penicillin, 2000 U/ml streptomycin, and 250 μg/ml fungizone), plated in tissue culture flasks and returned to a cell culture incubator (37°C, 5% CO₂). After 2–5 days, non-adherent cells were removed and adherent cells were collected separately and used for ROS assays using 2,7-dichlorofluorescein diacetate (H2DCF-DA, Molecular Probes) according to the manufacturer’s instructions. In brief, cells were treated with either media alone or supplemented with doxorubicin (0.01 μg/ml) for 20 hours. Next day, cells were trypsinized, washed and resuspended in PBS, combined with the molecular probe C400 (10 mg/ml) and incubated for 15 min at 37°C. Cells were analyzed using flow cytometry for C400 oxidation in the Vanderbilt University flow cytometry core [78].

RatLaps ELISA

To assess bone resorption, quantitative determination of bone-related degradation products from C-terminal telopeptides of type I collagen were measured using a commercially available ELISA assay kit (ImmunoDiagnosticsSystems, Catalog # AC-06F1) following the manufacturer’s guidelines. In brief, blood samples were collected from all animals on the same day (between 9:00 and 10:00 AM) at the end of the experiment and sera were prepared, as measuring the type I collagen fragments for in vivo models of bone disease, in order to avoid variability among samples. Serum samples were stored at −20°C, until the ELISA assay was performed. At least 9 samples per group were assessed.

RNA Isolation, cDNA Synthesis, and RT-PCR

MC3T3 murine osteoblast cell lines were cultured until 75% confluence and then treated either with media alone, doxorubicin (0.01 μg/ml), 1D11 (25 μg/ml) and a combination of doxorubicin and 1D11. Cells were harvested after 20 hours, washed by PBS and used for RNA isolation and cDNA preparation as described earlier [79]. Specific PCR conditions and primer design for OPG, RANKL, and GAPDH were described earlier [79]. In brief, RANKL and GAPDH were amplified using 94°C for 2 minutes followed by 35 cycles of 94°C for 15 seconds, 60°C for 30 seconds, 72°C for 45 seconds annealing, and a final extension of 72°C for 10 minutes. For OPG, PCR conditions were 94°C for 2 minutes followed by 35 cycles of 94°C for 15 seconds, 57°C for 30 seconds, 72°C for 45 seconds annealing, and a final extension of 72°C for 10 minutes. For SOD1 and GPx amplification [80], PCR conditions were 94°C for 2 minutes followed by 25 cycles of 94°C for 15 seconds, 57°C for 30 seconds, 72°C for 45 seconds annealing, and a final extension of 72°C for 10 minutes. Using methods described by Gevorgyan et al [81] OCN (bone Gla protein) was amplified using 94°C for 2 minutes followed by 25 cycles of 94°C for 1 minute, 58°C for 45 seconds, 72°C for I minute annealing, and a final extension of 72°C for 10 minutes. Similarly, secreted phosphoprotein 1(OPN) was amplified using 94°C for 2 minutes followed by 18 cycles of 95°C for 1 minute, 55°C for 2 minutes, 72°C for I minute annealing, and a final extension of 72°C for 10 minutes [81]. The PCR products were electrophoresed in 2% agarose gels. Images were captured using a BioRad gel documentation system and band intensities were quantified using Image J software. The following sets of primers were used for RT-PCR:

| Gene | Forward | Reverse |
|------|---------|---------|
| OCN  | 5'-CGTTGCTTCAGTGTGGC-3' | 5'-GGTGAAGATGGCTGAGG-3' |
| OPN  | 5'-GTGAGTCTGGAGATGAG-3' | 5'-GGTGAAGATGGCTGAGG-3' |
| SOD1 | 5'-TACCAATTCTGGAAGAAGTGTGC-3' | 5'-GTGAGTCTGGAGATGAG-3' |

SOD1 Activity

Effect of doxorubicin on SOD1 enzyme activity was measured in MC3T3 cells using Superoxide Dismutase assay kit ( Trevigen, Catalog # 7500-100-K). In brief, cells were plated in T75 flasks and treated for 20 hours in either serum free alpha-MEM media alone, or supplemented with 0.01 μg/ml doxorubicin, 25 μg/ml
anti-TGFβ antibody and a combination of both doxorubicin and anti-TGFβ antibody. Next day, both floating and attached cells were collected and centrifuged at 300 g for 10 minutes. Media was aspirated and cells were briefly washed using ice cold phosphate buffered saline using previous centrifugation speed. The pellet was resuspended using 10 volume lysis buffer, transferred to an Eppendorf tube and placed in an incubator for 30 minutes with periodic vortexing followed by centrifugation at 10,000 g for 10 minutes in a refrigerated Eppendorf centrifuge. The supernatant was transferred to a fresh pre-chilled Eppendorf tube and subjected to chloroform ethanol extraction. The upper aqueous phase was used for SOD1 activity assay. The inhibition of SOD1 activity was measured by formation of NBT-diformazan from NBT by colorimetric assay.

Statistical Analysis
Student’s T-test was used to determine the statistical significance of the results. A P-value <0.05 was considered statistically significant. At least 5–6 mice per group were used for each in vivo and in vitro experiment. All in vitro experiments using cell lines were performed at least three times.

Supporting Information

**Figure S1** Histological sectioned stained with H&E were used or tumor area assessment. Images were taken and were quantified using Metamorph software. At least five animals were in each group. A ratio of trabecular area versus tumor area was used to generate the ratio.

**References**

1. Mundy, GR, Guise, TA (1997) Hypercalcemia of malignancy. Am J Med 103: 134–145.
2. Guise, TA (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist 11: 1121–1131.
3. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martinos S, et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 586–592.
4. Shusterman S, Meadows AT (2000) Long term survivors of childhood leukemia. Curr Opin Hematol 7: 217–222.
5. Hadji P, Ziller M, Maskow C, Albert U, Kalder M (2009) The influence of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am 66: 602–607.
6. Young DM, Fioravanti JL, Olson HM, Prieur DJ (1975) Chemical and morphologic alterations of rabbit bone induced by adriamycin. Calcif Tissue Res 10: 47–63.
7. Glachin CA, Murray EJ, Murray SS (1992) Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells. Biochem Biophys Res Commun 18: 67–75.
8. Buttiglieri S, Ruella M, Riso A, Spatola T, Silengo L, et al. (2011) The aging effect of chemotherapy on cultured human mesenchymal stem cells. Exp Hematol 39: 1171–1181.
9. Biswas S, Guix M, Richeart C, Dugger TC, Chytli A, et al. (2007) Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117: 1305–1313.
10. Li J, Deane JA, Campanale NV, Bertram JF, Ricardo SD (2006) Blockade of p38 mitogen-activated protein kinase and TGF-beta1/Smad signaling pathways rescues bone marrow-derived peribulbar capillary endothelial cells in adriamycin-induced nephrosis. J Am Soc Nephrol 17: 2799–2811.
11. Buij J, Staynov KD, Guise TA (2013) TGF-beta in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenvironment 4: 261–281.
27. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H (2001) Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun 288: 275–279.
28. Maggio D, Barabani M, Pierandrei M, Polidori MC, Canali M, et al. (2003) Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88: 1525–1527.
29. Yalin S, Bagis S, Polat G, Dogruer N, Cekin Aksit S, et al. (2005) Is there a role of free oxygen radicals in primary male osteoporosis? Clin Exp Rheumatol 23: 609–622.
30. Osman B, Michaelsson K, Hemmersson J, Byberg L, Gedeborg R, et al. (2009) Oxidative stress and bone mineral density in elderly men: antioxidant activity of alpha-tocopherol. Free Radic Biol Med 47: 660–673.
31. Muller FL, Song W, Liu Y, Chaudhuri A, Pieke-Dahl S, et al. (2006) Absence of Cu/Zn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radic Biol Med 49: 1993–2004.
32. Noor R, Mittal S, Iqbal J (2002) Superoxide dismutase–applications and relevance to human diseases. Med Sci Monit 8: RA210–215.
33. Ahindag O, Erel O, Soran N, Celik H, Seleek S (2008) Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int 28: 117–120.
34. Finzel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408: 239–247.
35. Sanchez-Rodriguez MA, Ruiz-Ramos M, Correa-Munoz E, Mendoza-Nunez VM (2007) Oxidative stress as a risk factor for osteoporosis in elderly Mexicanas as characterized by antioxidant enzymes. BMC Musculoskelet Disord 8: 124.
36. Karsenty G, Wagner EF (2002) Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2: 389–406.
37. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176.
38. Bucy N, Sarosi I, Dunstan CR, Morony S, Tarpley J, et al. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260–1268.
39. Yasuda H, Shima N, Nakaawaga N, Yamauchi K, Kinoshita M, et al. (1998) Osteoclast differentiation factor as a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95: 3597–3602.
40. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17–25.
41. Zhou S, Palmeira CM, Wallace KB (2001) Doxorubicin-induced persistent oxidative stress to cardiomyocytes. Toxicol Lett 121: 151–157.
42. Wu CY, Steffen E, Ide D (2009) Cytosolic superoxide dismutase (SOD1) is critical for tolerating the oxidative stress of zinc deficiency in yeast. PLoS One 4: e5706.
43. Chen JH, Ling R, Yao Q, Li Y, Chen T, et al. (2005) Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model. Endocr Relat Cancer 12: 93–100.
44. Rosenstock JG, Jones PM, Pearson D, Palmer MK (1978) Ewing’s sarcoma, synovial sarcoma and osteosarcoma: response to preoperative and adjuvant chemotherapy and pathologic fracture. Eur J Cancer 14: 799–803.
45. Basu S, Michaelsson K, Liu Y, Palmeira CM, Wallace KB (2001) Doxorubicin-induced persistent oxidative stress to cardiomyocytes. Toxicol Lett 121: 151–157.
46. Ruoslahti E, Wu J, Vainio S, Pietinen P, Huttunen A (1998) A peroxiintersgenic factor in an adult treated for a metastatic sarcoma of the shaft of the femur with chemotherapy, tumour resection and endoprosthetic arthroplasty. Arch Orthop Trauma Surg 113: 224–226.
47. Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80: 1546–1556.
48. Pfeilschifter J, Oechsner M, Naumann A, Gronwald RG, Minne HW, et al. (1980) The cytoprotective Nrf2 transcription factor controls TGF-beta-induced osteoclast differentiation and vimentin activating transcription factor 1 (ATF4) axis. J Biol Chem 275: 5973–5984.
49. Nojiri H, Saita Y, Morikawa D, Kohayashi K, Tsuda C, et al. (2011) Cytoplasmic superoxide dismutase causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking. J Bone Miner Res 26: 2682–2694.
50. Smetana MJ, Arruda EM, Faulkner JA, Brooks SV, Larink LM (2010) Reactive oxygen species on bone mineral density and mechanics in Cu/Zn superoxide dismutase (Sod1) knockout mice. Biochim Biophys Biophys 403: 149–153.
51. Choi YJ, Lee JY, Chung CP, Park YJ (2012) Cell-penetrating superoxide dismutase attenuates oxidative stress-induced osteoclasts by regulating the p53-p14AIP1 pathway and restores osteoblast differentiation in human dental pulp stem cells. Int J Nanomedicine 7: 5091–5106.
52. Emerit J, Samuel D, Pavio N (2006) Cu-Zn super oxide dismutase as a potential antiatherosclerotic for hepatitis C related fibrosis. Biomed Pharmacother 60: 1–4.
53. Yamasaki-Tsukada M, Suvor V, Gauth N, Renard C, Gheffrin C, et al. (2001) Antifibrotic action of Cu/Zn SOD is mediated by TGF-beta1 repression and phenotypic reversion of myofibroblasts. Free Radic Biol Med 30: 30–42.
54. Manomet Dittmar1, Melanie Kuhn2, Marc Benecke3 and Bernd Epe4 (2008) The Open Anthropology Journal 1: 38–40.
55. Hussain SP, Amstad P, Pe H, Robles A, Lapold S, et al. (2004) p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 64: 2350–2356.
56. Yoneteda T, Williams PJ, Hiraga T, Niewoehn M, Nishimura R (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16: 1406–1495.
57. Asakawa CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399–1405.
58. Rose AA, Peppin F, Russo C, Aloba Khalife JF, Hallett M, et al. (2007) Osteoclastin promotes breast cancer metastasis to bone. Mol Cancer Res 5: 1001–1014.
59. Campbell JP, Karolak MR, Ma Y, Perren DS, Masood-Campbell SK, et al. (2012) Stimulation of host bone marrow stromal cells by sympathetic nerve fibers promotes metastases development in vivo by local growth factor release. PLoS Biol 10: e1001363.
60. Galbovitz WE, Gause TA, Mundy GR (2002) Guanosine nucleotides inhibit transforming growth factor beta suppression of osteoblast differentiation and osteoblast and osteoclast tumor cell lines. J Clin Invest 109: 197–206.
61. Bellows GG, Hersche RN, Aussen JA (1989) Effects of demethasone on expression and maintenance of rabbit carotid artery in serum-containing cultures of calvaria cells. Cell Tissue Res 256: 143–151.
62. Robey PG, Termine JD (1985) Human bone cells in vitro. Calcif Tissue Int 37: 453–460.
63. Beyer TA, Werner S (2003) The cytoprotective Nrf2 transcription factor controls insulin receptor signaling in the regenerating liver. Cell Cycle 7: 874–878.
64. Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, et al. (2005) Reactive oxygen species on bone mineral density and mechanics in Cu/Zn superoxide dismutase (Sod1) knockout mice. Biochim Biophys Res Commun 403: 149–153.
65. Yin JJ, rugina K, Chirgwin JM, Dallas M, Grubbs BG, et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197–206.
66. Bellose MG, Heersche RN, Aussen JA (1989) Effects of demethasone on expression and maintenance of rabbit carotid artery in serum-containing cultures of calvaria cells. Cell Tissue Res 256: 143–151.
67. Gevorgyan A, Sukhu B, Alman BA, Brisset GW, Pang CY, et al. (2008) Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells. Plast Reconstr Surg 122: 1025–1033.